Peter Wedlund - Ph.D.

Dr. Wedlund's primary research interest is the study of how genetic factors affect the elimination response and toxicity of drugs. The laboratory utilizes the polymerase chain reaction (PCR) and restriction fragment length polymorphisms (RFLP's) along with analytical methods (HPLC and GC) to understand how differences at the DNA level affect drug elimination and response. The clinical research attempts to assess the relevance of genetic variability on therapy and therapeutic outcomes. The laboratory is supported in part by the Center for Pharmacogenetic Studies and Testing, which phenotypes and genotypes samples obtained from the pharmaceutical industry. Current projects include "Genetic variation in the CYP2D6 enzyme in psychiatric patients," "Mechanism(s) responsible for extremes in warfarin therapy," "The role of the CYP2D6 enzyme variation in renal disorders" and "Assessing the relevance of CYP2D6 genetic variation in the elderly." The purpose of the research is to define the importance and relevance of genetic variation in patient therapy and on patient costs and to integrate genetic testing into clinical practice when it provides an obvious therapeutic benefit.

Selected Publications/Presentations

• H Wang, AA Hussain, PJ Wedlund. Systemic Availability of Nipecotic Acid (NA) after intravenous (IV) and intranasal administration of its butyl ester (BNA) to rats. AAPS Pharmaceutics Meeting, Toronto, CA (November 12-15, 2002).
• H Wong, AH Hussain, JS Pyrek, JP Goodman, PJ Wedlund. Assay for Nipecotic acid in small biological samples by gas chromatography-mass spectroscopy. AAPS Pharmaceutics Meeting, Denver, CO (October 22-25, 2001).
• H. Wang, A. Hussain, A. Al-Ghananeem, P. Wedlund, "Enzymatic hydrolysis of O-2-Acetoxybenzyl-salicylamide. A potent oral analgesic. American Association for Pharmaceutical Scientists (AAPS) Meeting, New Orleans, LA, November 1999.
• M. Ihnen, FX Yan, PJ Wedlund, P. Fanti: Combined deficiency in glutathhione S-transferase-M1 (GST-M1) and T1 (GST-T1) genes is associated with high levels of parathyroid hormone (PTH) in ESRD.Clinical Nephrology Meeting. Atlanta, GA, April 13-16, 2000.
• MC Langub, E Juronen, PJ Wedlund, P Fanti. Immunohistochemical localization of the detoxifying enzymes CYP2D6, GST-M1 and GST-T1 in human and porcine parathyroid tissue (PT). J.Amer.Soc.Nephrol. 12: 767A, 2001. Meeting Oct. 21-25, 2001.
• W.H. Koch, M. Fairchild, W.H. Chou, F.X. Yan, D.K. Robbins-Weilert, T. Ryder, W.W. Liu, C. Peerbost, P.J. Wedlund: Cytochrome P450-2D6 (CYP2D6): Comparison of Genotyping by Allele-specific PCR with oligonucleotide microarray hybridization and correlation with in-vivo Enzyme activity. International Federation of Clinical Chemists Meeting, Kyoto Japan, April 16-19, 2000.
• WM Cai and PJ Wedlund: In vivo inhibition of dextromethorphan metabolism by terbinafine. American Society of Clinical Pharmacology and Therapeutics, Lake Buena Vista, Florida, March, 2001.
• WM Cai, R Pan, M Ihnen, MC Langub, P Fanti, PJ Wedlund: Polymorphisms in drug metabolism enzymes in patients with end stage renal disease (ESRD). AAPS Pharmaceutica Meeting, Denver, CO (October 22-25, 2001).